<p>Introduction - Stephen Neidle</p> <p>Foreword - Hilary Calvert</p> <p>Part I. Basic Principles and methodology</p> <p>Modern cancer drug discovery: integrating targets, technologies and treatments — Paul Workman and<br>Ian Collins</p> <p>Pharmacogenomics and personalised medicines in cancer treatment — Wei-Peng Yong, Ross Soo and<br>Federico Innocenti</p> <p>Structural biology and anticancer drug design — Puja Pathuri, David Norton, Henriette Willems,<br>Dominic Tisi and Harren Jhoti</p> <p>Part II. Drugs in the laboratory and clinic</p> <p>Temozolomide: from cytotoxic to molecularly-targeted agent — Malcolm Stevens</p> <p>Temozolomide: patents and the perils of invention — Malcolm Stevens</p> <p>A new generation of cell-targeted drugs for cancer treatment — Paola B. Arimondo, Nicolas Guilbaud<br>and Christian Bailly</p> <p>Inhibition of DNA repair as a therapeutic target — Stephany Veuger and Nicola J Curtin<br>Inhibitors of tumour angiogenesis — Adrian L. Harris and Daniele G Generali</p> <p>The Renaissance of CYP17 Inhibitors for the Treatment of Prostate Cancer — Qingzhong Hu and Rolf<br>W. Hartmann</p> <p>Apoptosis in Cancer: Mechanisms, Deregulation and Therapeutic Targeting — Zahid H Siddik</p> <p>Targeting the MDM2-p53 protein-protein interaction: design, discovery and development of novel<br>anticancer agents — Ian R Hardcastle</p> <p>Targeting altered metabolism – emerging cancer therapeutic strategy — Minsuh Seo, Robert Blake<br>Crochet and Yong-Hwan Lee</p> <p>Inhibitors of the Phosphatidylinositol 3-kinase (PI3K) Pathway — William A Denny and Gordon W.<br>Rewcastle</p> <p>Antibody-drug conjugates delivering DNA cytotoxics — John A Hartley</p> <p>Inhibition of telomerase: promise, progress and potential pitfalls — Christopher G. Tomlinson, Scott B.<br>Cohen and Tracy M. Bryan</p> <p>Targeting B-RAF: the discovery and development of B-RAF inhibitors — Phillip A Harris</p> <p>Part III. The reality of cancer drugs in the clinic</p> <p>Failure Modes in Anticancer Drug Discovery and Development — Richard A. Walgren and<br>Christopher. A. Slapak</p> <p>Anticancer drug registration and regulation: current challenges and possible solutions — David<br>Taylor, Erling Donnelly and Silvia Chioato</p>
